INTRODUCTION AND OBJECTIVES: Current non-invasive approaches for bladder cancer (BC) detection are suboptimal. In this study, we report the development of a non-invasive molecular assay (UroSEEK) for detection of BC recurrence during disease surveillance using DNA recovered from cells shed into urine. UroSEEK incorporates assays for mutations in 11 genes and copy number changes on 39 chromosome arms.
INTRODUCTION AND OBJECTIVES: Current non-invasive approaches for bladder cancer (BC) detection are suboptimal. In this study, we report the development of a non-invasive molecular assay (UroSEEK) for detection of BC recurrence during disease surveillance using DNA recovered from cells shed into urine. UroSEEK incorporates assays for mutations in 11 genes and copy number changes on 39 chromosome arms.
METHODS: Urine samples were collected prospectively from patients with previously established diagnosis of BC from two institutions. Patients with a known history of malignancy other than BC were excluded. Urine samples were analyzed for mutation in three component assays: First, a multiplex PCR was used to detect mutations in regions of CDKN2A, ERBB2, FGFR3, HRAS, KRAS, MET, MLL, PIK3CA, TP53, and VHL. Second, an amplification primer was used to amplify a 73-bp segment containing the region of the TERT promoter. Aneuploidy was assessed with FastSeqS, which uses a single primer pair to amplifye38,000 loci scattered throughout the genome. Follow up data was obtained from medical records.
RESULTS: 322 patients were identified, 187 had biopsy proven recurrence. The multiplex PCR assay detected mutations in 52% patients that developed recurrent BC. The most commonly altered genes were TP53 and FGFR3 (38% and 29% of the 200 mutations; respectively). Mutations in TERT promoter were detected in 57% of samples and aneuploidy was detected in 28% of samples from patients with recurrent disease. The most commonly altered chromosomal arms were 8p, 8q, and 9p. In patients with BC recurrence, 127/187 samples were positive for at least one of the three UroSEEK componont assays for a sensitivity of 68% and a specificity of 80%.
In combination with cytology UroSEEK demonstrated 71% sensitivity and 82% specificity. One-hundred patients had "atypical" diagnosis on cytology. Among the latter, UroSEEK was positive in 68% of 71 patients that recurred with a 83% specificity and a mean lead time from biopsy proven recurrence of 6 months (range 0 -35). Cytology did not detect recurrent low-grade tumors while UroSEEK detected 67% of them. Cytology detected 41% of high-grade tumors while UroSEEK detected 71%.
CONCLUSIONS: UroSEEK raised the sensitivity of cytology from 25% to 71% and detected recurrence in 68% of atypical cytology patients. UroSEEK positivity preceded clinical diagnosis by months to years. Prospective trials are required to demonstrate the ability of UroSEEK to improve outcome in BC surveillance.
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MP65-15 HUMANIZED ANTI-CD47 ANTIBODY (HU-5F9-G4) FOR METASTATIC BLADDER CANCER IS SUPERIOR TO CONVENTIONAL CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN A MURINE BLADDER CANCER MODEL.
Bernhard Kiss*, Anne Volkmer, Joseph Liao, Jens-Peter Volkmer, Irving Weissman, Stanford, CA INTRODUCTION AND OBJECTIVES: Antibody-dependent phagocytosis by cells of the innate immune system, such as macrophages and dendritic cells, is a major mechanism of action of many antibodies for cancer treatment and one mainstay of cancer immunotherapy. One mechanism of tumors to prevent phagocytosis and thus avoid removal is to up regulate 00 don 0 t eat me 00 signals. CD47 has been discovered as such a 00 don 0 t eat me 00 signal. CD47 binds a receptor on the immune cells, SIRP-alpha, which in turn delivers an inhibitory signal for phagocytosis. CD47 antibodies are in clinical development for several tumor types and CD47 is also expressed on more than 80% of bladder cancer cells. Therefore, our aim was to investigate the effect of Hu5F9-G4, a humanized CD47 blocking antibody, on bladder cancer growth and metastases alone as well as in combination with standard chemotherapy for bladder cancer.
METHODS: First, Hu5F9-G4 mediated phagocytosis of urothelial bladder cancer cells (639V cancer cell line, previously transduced with a GFP-Luciferase encoding lentivirus) by mouse and human macrophages (from 3 different donors) was evaluated in vitro. Next, treatment was evaluated in a xenograft mouse model in vivo. Bladder cancer cells (150,000 639V cells in 50% regular matrigel) were transplanted subcutaneously onto the back of 8-10-week-old male NSG mice. Upon confirmation of engraftment by bioluminescent in vivo imaging, mice were randomized into 4 different treatment cohorts with 6 mice per cohort. Cohort A received PBS (twice a week for 4 weeks), Cohort B received Hu5F9-G4 alone (250g twice a week for 4 weeks), Cohort C received chemotherapy (Cisplatin 2.5 mg/kg and Gemcitabine 25 mg/kg weekly for 4 weeks) and Cohort D received chemotherapy for 4 weeks followed by Hu5F9-G4 for 4 weeks. All drugs were administered intra-peritoneal. Tumor growth was monitored by in vivo bioluminescent imaging, performed on an IVIS spectrum (Caliper Life Science), and quantified using Living Image software. Metastases were investigated postmortem under fluorescent light for GFP expression using a confocal microscope.
RESULTS: In vitro phagocytosis assays showed a statistically significant increase in cancer-cell phagocytosis when treating the cancer-cells with Hu5F9-G4 compared to PBS, using macrophages from mice as well as from human (p¼0.0001 and p<0.0001 respectively).In vivo bioluminescence analyses showed a significantly decrease of tumor growth in the Hu5F9-G4 as well as chemotherapy treated cohorts. Tumor growth after 6 weeks in Cohort B [median fold change(FC) 3,6], C [median FC 11, 4] and D [median FC 8, 9] compared to Cohort A [median FC 28, 2] . Because of high tumor burden in PBS treated group the mice in Cohort A had to be sacrificed preliminary after 6 weeks. Animals of all other groups reached the endpoint of 8 weeks. Metastases formation in the liver and the lungs was almost completely inhibited by treatment with Hu5F9-G4, whereas animals in the groups treated with chemotherapy showed metastases in the liver and lungs.
CONCLUSIONS: Blocking CD47 using the humanized antibody Hu5F9-G4 is an effective method of treating bladder cancer in vitro and in vivo and shows superior suppression of primary tumor growth as well as metastases compared to conventional chemotherapy with Cisplatin and Gemcitabine . 199, No. 4S, Supplement, Sunday, May 20, 2018 
